Trials / Active Not Recruiting
Active Not RecruitingNCT06962280
A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy and Long-Term Safety of Tirzepatide Once Weekly Compared to Placebo in Adults With Type 1 Diabetes and Obesity or Overweight
- Status
- Active Not Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 465 (estimated)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to find out how well and how safely tirzepatide works long-term in adults who have type 1 diabetes and obesity or overweight. Participation in the study will last about 20 months.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tirzepatide | Administered SC |
| DRUG | Placebo | Administered SC |
Timeline
- Start date
- 2025-05-12
- Primary completion
- 2026-11-01
- Completion
- 2027-07-01
- First posted
- 2025-05-08
- Last updated
- 2026-02-17
Locations
79 sites across 10 countries: United States, Argentina, Brazil, Canada, Czechia, France, Greece, Mexico, Romania, Spain
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06962280. Inclusion in this directory is not an endorsement.